⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25692446 | 1.00 | — | — | |
| SCHEMBL26184207 | 1.00 | — | — | |
| SCHEMBL30181708 | 1.00 | — | — | |
| SCHEMBL8565318 | 1.00 | — | — | |
| SCHEMBL15846869 | 0.77 | — | — | |
| SCHEMBL1853773 | 0.77 | — | — | |
| SCHEMBL4369331 | 0.77 | — | — | |
| SCHEMBL17132888 | 0.77 | — | — | |
| SCHEMBL17125764 | 0.77 | — | — | |
| SCHEMBL17125765 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230174518-A1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| US-9969730-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170226104-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS INC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170035741-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2017-02-09 | — | — | US | disclosed |
| US-9469635-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150157614-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20140275547-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8802719-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140171660-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS, INC. | 2014-06-19 | — | — | US | disclosed |
| US-8586601-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8497282-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8138202-B2 | Stable SNS-595 compositions and methods of preparation | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110086876-A1 | STABLE SNS-595 COMPOSITIONS AND METHODS OF PREPARATION | SUNESIS PHARMACEUTICALS, INC. | 2011-04-14 | — | — | US | disclosed |
| US-20110082169-A1 | Stable SNS-595 Compositions and Methods of Preparation | SUNESIS PHARMACEUTICALS, INC. | 2011-04-07 | — | — | US | disclosed |